Construction of antibody-library to identify etiology-associated-antigen
构建抗体库来鉴定病因相关抗原
基本信息
- 批准号:15591075
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2003
- 资助国家:日本
- 起止时间:2003 至 2004
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Background & Aims : The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis(PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods : We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results : Patients were classified into 3 groups : Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid(UDCA) therapy, Group C in whom anti-gp21 0 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusion : The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
背景与目的:核孔复合物糖蛋白(gp210)抗体的存在是原发性胆汁性肝硬化(PBC)的高度指示性。然而,抗gp210抗体滴度对PBC监测的意义尚不清楚。方法:采用以gp210 c端肽为抗原的ELISA检测71例PBC患者的血清抗体滴度。结果:将患者分为3组:A组患者抗gp210滴度维持在高水平,B组患者抗gp210在熊去氧胆酸(UDCA)治疗下由阳性变为阴性,C组患者诊断时抗gp210抗体为阴性。与B组(0%)和C组(4.2%)相比,A组(60%)进展为终末期肝衰竭的比率明显更高。对gp210的持续抗体反应与界面肝炎的严重程度密切相关。抗gp210抗体的意义由日本国立肝病医院组织研究组证实。结论:血清抗gp210- c末端肽抗体的连续定量检测有助于监测UDCA的效果,有助于早期发现终末期肝衰竭高危患者。
项目成果
期刊论文数量(29)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Antibody titer to gp210-C terminal peptide as a clinicai parameter for monitoring primary biliary cirrhosis
gp210-C 末端肽抗体滴度作为监测原发性胆汁性肝硬化的临床参数
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Nakamura M;Shimizu-Yoshida Y;Takii Y;et al.
- 通讯作者:et al.
Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Sakamoto N, Matsushita S, Tanaka A, Worman HJ, Gershwin M.E, Harada M: "Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis."Gastroenterology. 124. 1915-1925 (2
Shimoda S、Nakamura M、Ishibashi H、Kawano A、Kamihira T、Sakamoto N、Matsushita S、Tanaka A、Worman HJ、Gershwin M.E、Harada M:“原发性胆汁性肝硬化中线粒体和核自身抗原的分子模拟。”胃肠病学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
中村 稔, 下田慎治, 石橋大海: "原発性胆汁性肝硬変における分子擬態の役割"BIO Clinica 18(8). 2. 695-551 (2003)
Minoru Nakamura、Shinji Shimoda、Taikai Ishibashi:“分子拟态在原发性胆汁性肝硬化中的作用”BIO Clinica 18(8) (2003)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kamihira T, Shimoda S, Harada K, Kawano A, Handa M, Baba E, Tsuneyama K, Nakamura M, Ishibashi H, Nakamura Y, Gershwin ME, Harada M: "Characterization of distinct costimulation dependent and independent autoreactive T cell clones in primary biliary cirrho
Kamihira T、Shimoda S、Harada K、Kawano A、Handa M、Baba E、Tsuneyama K、Nakamura M、Ishibashi H、Nakamura Y、Gershwin ME、Harada M:“原代细胞中不同共刺激依赖性和独立自身反应性 T 细胞克隆的表征
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Promiscuous T cells selected by Escherichia coli: OGDC-E2 in primary biliary cirrhosis.
由大肠杆菌选择的混杂 T 细胞:原发性胆汁性肝硬化中的 OGDC-E2。
- DOI:10.1016/s0896-8411(03)00024-6
- 发表时间:2003
- 期刊:
- 影响因子:12.8
- 作者:Tanimoto,Hironori;Shimoda,Shinji;Nakamura,Minoru;Ishibashi,Hiromi;Kawano,Akira;Kamihira,Takashi;Matsushita,Sho;Gershwin,MEric;Harada,Mine
- 通讯作者:Harada,Mine
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAKAMURA Minoru其他文献
Identification of the casual variants in human primary biliary cirrhosis (PBC) by the combination of a genome-wide association study, Whole-genome sequencing, and in silico/ in vitro functional analyses.
通过结合全基因组关联研究、全基因组测序和计算机/体外功能分析,鉴定人类原发性胆汁性肝硬化 (PBC) 的偶然变异。
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
HITOMI Yuki;AIBA Yoshihiro;YASUNAMI Michio;NAKAMURA Minoru;TOKUNAGA Katsushi. - 通讯作者:
TOKUNAGA Katsushi.
NAKAMURA Minoru的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAKAMURA Minoru', 18)}}的其他基金
Genome-wide associationstudy to detect disease-associated genes in Japanese patients with primary biliary cirrhosis
全基因组关联研究检测日本原发性胆汁性肝硬化患者的疾病相关基因
- 批准号:
23591006 - 财政年份:2011
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
New clinical classification and the criteria for predicting long-term outcome in primary biliary cirrhosis
原发性胆汁性肝硬化的新临床分类和长期结局预测标准
- 批准号:
20590800 - 财政年份:2008
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new molecular targets and the study for the mechanism of bile ducts-and hepatocyte-destruction in primary biliary cirrhosis
原发性胆汁性肝硬化新分子靶点的鉴定及胆管和肝细胞破坏的机制研究
- 批准号:
17590696 - 财政年份:2005
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification and characterization of T cell epitope in primary biliary cirrhosis
原发性胆汁性肝硬化 T 细胞表位的鉴定和表征
- 批准号:
11694287 - 财政年份:1999
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
FUNCTIONAL AND DNA ALALYSIS OF THE NOVEL PROTEIN (R21 PROTEIN) INVOLVED IN MEMBRANE FUSION
参与膜融合的新型蛋白质(R21 蛋白质)的功能和 DNA 分析
- 批准号:
10670416 - 财政年份:1998
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of HTLV-1 neutralizing epitopes and the development of an HTLV-1 peptide based vaccine
HTLV-1 中和表位的鉴定以及基于 HTLV-1 肽的疫苗的开发
- 批准号:
04670391 - 财政年份:1992
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Alterations of aryl hydrocarbon receptor signaling in autoimmune hepatitis
自身免疫性肝炎中芳烃受体信号传导的改变
- 批准号:
10263370 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
A Multiomic Search for Antigens in Autoimmune Hepatitis
自身免疫性肝炎抗原的多组学研究
- 批准号:
10263272 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
Elucidation of the onset mechanism of Type 2 Autoimmune Hepatitis and related liver diseases
阐明2型自身免疫性肝炎及相关肝脏疾病的发病机制
- 批准号:
20H03466 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Alterations of aryl hydrocarbon receptor signaling in autoimmune hepatitis
自身免疫性肝炎中芳烃受体信号传导的改变
- 批准号:
10463827 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
Alterations of aryl hydrocarbon receptor signaling in autoimmune hepatitis
自身免疫性肝炎中芳烃受体信号传导的改变
- 批准号:
10117722 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
LiverMultiScan for clinical decision making in Autoimmune Hepatitis
LiverMultiScan 用于自身免疫性肝炎的临床决策
- 批准号:
104915 - 财政年份:2019
- 资助金额:
$ 2.24万 - 项目类别:
CR&D Bilateral
Investigating the Effects of Farnesylation on an Autoimmune Hepatitis Model
研究法呢基化对自身免疫性肝炎模型的影响
- 批准号:
19K09374 - 财政年份:2019
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Comprehensive analysis of exosomes in autoimmune hepatitis and involvement in pathology
外泌体在自身免疫性肝炎中的综合分析及参与病理学的研究
- 批准号:
19K08447 - 财政年份:2019
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Autoimmune Hepatitis: Genetic and Environmental Risks
自身免疫性肝炎:遗传和环境风险
- 批准号:
10445144 - 财政年份:2018
- 资助金额:
$ 2.24万 - 项目类别:
Autoimmune Hepatitis: Genetic and Environmental Risks
自身免疫性肝炎:遗传和环境风险
- 批准号:
9898370 - 财政年份:2018
- 资助金额:
$ 2.24万 - 项目类别: